BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DalCor Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies DalCor Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05918861-1099@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Dalcetrapib: Phase 3 readout est. (NCT05918861)
DESCRIPTION:Dalcetrapib\, phase 3\, Atherosclerotic Cardiovascular Disease.
 \nStudy: Effect of Dalcetrapib on CV Risk in a Genetically Defined Populat
 ion With a Recent ACS\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dalcetrapib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05918861
URL:https://assetmemo.bio/drug/dalcetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
